Day One Biopharmaceuticals (DAWN) IPO Opens 56% Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Medifast launches Trilivy, replacing its Optavia brand
- Adobe has received a takeover approach by a Big Tech company - Betaville
Day One Announces Pricing of Upsized Initial Public Offering
May 26, 2021 10:30 PM EDTSOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00Â per share. All of the shares are being offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, are expected to be $160.0... More
